Protalix Biotherapeutics Inc (PLX) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.61x

Protalix Biotherapeutics Inc (PLX) has a Cash Flow Reinvestment Rate of 0.61x as of December 2025, reinvesting $1.24 Million (capex $1.24 Million ) from operating cash flow of $2.03 Million. Explore PLX capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.61x
(Capex + Investments) / Operating CF

Total Reinvested

$1.24 Million
Capex + Investments

Operating Cash Flow

$2.03 Million
USD

Capital Expenditures

$1.24 Million
USD

Protalix Biotherapeutics Inc Cash Flow Reinvestment Rate (2009–2024)

Historical reinvestment intensity for Protalix Biotherapeutics Inc across 3 annual periods. Also explore Protalix Biotherapeutics Inc total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Protalix Biotherapeutics Inc (2009–2024)

Year-by-year capital reinvestment analysis for Protalix Biotherapeutics Inc. For live market cap and broader valuation context, see PLX market cap.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 0.63x $5.50 Million $8.67 Million $1.28 Million ▼ -80.5%
2012 3.26x $2.07 Million $635.00K $2.07 Million ▲ +2236.8%
2009 0.14x $6.20 Million $44.45 Million $6.20 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow